Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AC5 Application ? #218? AC5 loaded with star-shaped peptide polymer $ARTH
There are so many potential topical applications for AC5
Sep. 26, 2016 03:21PM EST
Scientists Are Freaking Out Over This 25-Year-Old’s Solution to Superbugs
http://www.ecowatch.com/shu-lam-superbugs-2017264440.html
“The quickest way to make this available to the public is through topical application, simply because you go through less procedures as opposed to ingesting these molecules into the body. So when you have a wound or a bacterial infection on the wound then you [generally] apply some sort of antibacterial cream.
BigKahuna
Why does this stock have 438 followers and Arch has a measly 137?
http://investorshub.advfn.com/NanoViricides-Inc-NNVC-4102/
I just do not get it.
Here he is. In 2006-2009 as Dr. Rutledge Ellis-Behnke stated in video the AC5 version was crap compared to today's version.
Presentation by Founder and Inventor of AC5 Dr. Rutledge Ellis-Behnke PHD using AC5 on animals
AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals
You Tube Video--Watch
More ARCH Articles
New article (9/22/16) on AC5 in Surgery Products Magazine: "Arch Therapeutics Delivers New Method For Controlling Bleeding"
http://www.surgicalproductsmag.com/article/2016/09/arch-therapeutics-delivers-new-method-controlling-bleeding
"...The initial goal is to stop bleeding, which is also called hemostasis but the company has aspirations to leverage its technology to address leakage of other bodily fluids. There’s also an organizational commitment to trauma care and military medicine.
The first derivation of the technology Arch Therapeutics is pursuing is the AC5 Topical Hemostatic Device™.
The company recently got topline data from its first study of safety and performance in humans. It involved 46 patients, each of whom had at least two skin lesions on their arms or torso. After being removed, the wound defects, which were left behind, were treated with either AC5™ or a sham saline solution applied to it. The patients were reassessed after seven days and again after 30 days."
http://oracledispatch.com/2016/09/24/steady-progress-at-arch-therapeutics-inc-otcmktsarth/
Steady Progress at Arch Therapeutics Inc (OTCMKTS:ARTH)
By Jermaine Farmer - September 24, 2016
They early exercise the E warrants that expire May 26, 2021 at $.438 per share for $1.9 million total dollars. It means Arch has more money now and does not have to dilute by selling more shares. Great deal for Arch Shareholders....
Most people would hold the warrants for as long as possible. There is also an option of "cashless" exercise but that is a different ballgame.
What I believe Dr. Norchi was referring to is that the Maxim investors exercised their Series E warrants for $ 1.8 million so when the 10-Q comes out for 9/30/16 we will see that cash has changed.
ommenting on their cash position said: "We had about 12 months of runway and you'll hopefully hear more about that in the not-too-distant future."
Michaal Murphy is wrong....
Stock is up Friday and today because of this. He is flat out wrong. Anyone else know why?? Michael you have to do your homework !!
Dear New World Investor:
Last week, I reminded you that Arch Therapeutics (ARTH) is the current recovery trade, and it was just under my buy limit. I said the next driver for the stock would be signing a deal for European distribution, which should net them a milestone payment large enough to fund the FDA approval process.
In a presentation last week, Terry Norchi, the Chief Executive Officer with an MD and an MBA who used to run Putnam's healthcare fund, commenting on their cash position said: "We had about 12 months of runway and you'll hopefully hear more about that in the not-too-distant future."
CEOs, especially CEOs who have run a major healthcare fund and listened to hundreds of company presentations, do not throw out a tidbit like that unless a deal is imminent. Since Arch does not need cash soon, so it isn't a stock offering, this means to me that a European distribution deal is imminent. I immediately raised my buy limit.
GLTA,
Michael Murphy CFA
Articles mentioning ARCH and AC5
We are starting to see more and more of these.
https://issuu.com/md-publishing/docs/1607_ort-mag
page 26 and 46
Page 46 article
He makes comment in right hand corner
https://www.linkedin.com/in/richard-kocharian-9920638
Richard Kocharian
Franchise Medical Director, Biosurgery at ETHICON Inc., a Johnson&Johnson company
Arth Presentation
Dr. Norchi Webcast today--minutes 24 to 27 whole new product lines beyond AC5's 200 applications--it is endless with new patents being filed
http://wsw.com/webcast/aegis3/arth/index.aspx
Dr. Norchi comment regarding the AC5 +- 200 applications plus new potential product pipeline. "My view is that they're all big, and there's lots of them and that's why we're pretty excited."
Buy ARTH - Two Gifts for You Michael Murphy CFA
Sent: 9/20/2016 1:46:10 P.M. US Mountain Standard Time
Subj: Buy ARTH - Two Gifts for You
You opted-in to receive free stock and market updates when you subscribed to New World Investor. Easily unsubscribe by clicking the link at the very bottom of this newsletter.
Dear New World Investor:
My first gift: I want to be sure you know that Arch Therapeutics (ARTH) is the current recovery trade, and it is just under my buy limit. ARTH has a new, patented liquid that stops bleeding in seconds. It will be widely used in surgery, EMS situations, and on the battlefield. It is regulated as a device, not a drug, and therefore only needs one clinical trial for approval.
The company just finished a very successful clinical trial in Europe, and will apply for the CE mark by the end of the year. In 2017 they will complete a US trial and file for FDA approval.
What's really exciting about ARTH is that the US market alone for hemostats to stop bleeding is $5 billion. Arch's product is far superior to what's on the market now, yet the whole market capitalization of the company is only $80 million. The next drivers for the stock will be:
* * Signing a deal for European distribution, which should net them a milestone payment large enough to fund the FDA approval process
* * Publishing the European trial results in a peer-reviewed journal
* * Applying for the CE mark
* * Getting the CE mark
* * The US clinical trial
The company is run by an MD/MBA who used to run Putnam's healthcare fund. He's very financially sophisticated and owns a big block of the stock. At 60 cents a share, please check it out! My first target is $3.50, and I expect to see double-digits in a few years.
GLTA,
Michael Murphy CFA
Elevator Summary of Company http://www.archtherapeutics.blogspot.com/
Perhaps this is where anatabine belongs...
http://archive.fast-edgar.com//20160913/AAK2K22CK222Q2ZZ2A2N2CZZQDOAU2R2Z282/
"New refinancing round" You surely did not listen to the presentation. You must have the wrong stock.
ARTH Presentation
The meat is on Page 16--wish he spent the whole time on it. AC5 is but one of many products....
http://wsw.com/webcast/rrshq25/register.aspx?conf=rrshq25&page=arth&url=http://wsw.com/webcast/rrshq25/arth/index.aspx
Thanks. Courtesy of Dr. KSS
"Thus far in 2016, 89 percent of FDA-submitted medical device applications have been pushed back by the FDA with a citation of at least one major deficiency. This datum does place the plight of TransEnterix in interesting relief….almost as if it was gratuitously doomed.
That’s the highest in history.
The lowest was 40 percent in 2000. I don’t have data for n in either case."
So you have been in since 2013 and I saw you reference that we are in the top of the first inning?
I just wonder if they will not resubmit to FDA again?
How did you learn of TRXC? What are your thoughts about rumors of JNJ or IRSG acquiring? What impact will Pappas have?
Thank you
ARTH Cosmetic Surgery Times Article
Comment: Good to see Dr. Norchi stepping out with his comments on AC5 based on human trial--see bottom comments--expect to see more of this as Dr. Norchi receives more human clinical data---less scarring
Cosmetic Surgery Times
AC5 Topical Hemostatic Device achieves study endpoints
September 08, 2016By Bob Kronemyer
The first clinical study of the AC5 Topical Hemostatic Device from Arch Therapeutics Inc. (Framingham, Mass.) for skin lesions with bleeding wounds was found safe throughout the surgical procedure and up to 30-days postoperatively. Performance as assessed by time to hemostasis was also 41% faster than standard care.
“This hemostatic device is one of a set of products we are developing based on our self-assembling peptide technology,” says company president and CEO Terrence W. Norchi, M.D., in an interview with Cosmetic Surgery Times. “We believe these products have the potential to make a difference in patient care, leading to better outcomes while being a valuable tool in the surgeon’s or healthcare provider’s toolbox.”
Dr. Norchi explains that when the hemostatic device’s self-assembling peptide is exposed to a highly charged environment, such as a wound or salt water, “the interactions among and between the peptide’s amino acid side chains and that environment lead the peptide to assemble into a physical mechanical barrier. You typically can see the liquid become more gel-like at that time. This is a very different mechanism of action compared to other successfully commercialized products and we believe it will help make a difference for patients.”
The European 46-patient study included 10 patients who were on antiplatelet monotherapy. All patients had bleeding wounds from excision of at least two skin lesions under local anesthetic in the same setting.
“The trial was designed to focus primarily on safety because this is very important both for us and for the regulatory authorities,” Dr. Norchi says. “In fact, especially in the European Union (EU), one can argue that showing safety matters even more than efficacy in order to be allowed to sell a product.”
Arch Therapeutics expects to launch the AC5 Topical Hemostatic Device in Europe next year.
“In the near future, we hope to see data that show hematoma and seroma formation is lessened,” Dr. Norchi says. “We further anticipate that tissues will heal normally, even in patients who have underlying diseases such as diabetes. Thus, if all goes well, the patient’s outcome will be improved with less bruising — which are both cosmetically and medically troubling — along with less scar formation and normal healing. That would be a wonderful outcome.”
Apart from hemostasis, potential applications for the technology include sealants and prevention of surgical adhesions, gastrointestinal bleeding (peptic ulcers) and bleeding from antithrombotic medications (blood thinners). Wound care applications are also promising, such as hard-to-heal ulcers (pressure ulcers and diabetic foot ulcers), plus specialty applications like central nervous system surgery, burn care and plastic surgery.
“Patients who are having biopsies or skin procedures that leave them prone to bruising, hematomas and seromas, could potentially benefit as well,” Dr. Norchi says.
http://cosmeticsurgerytimes.modernmedicine.com/cosmetic-surgery-times/news/ac5-topical-hemostatic-device-achieves-study
Good to see you back! One could not have dreamed what has happened here.
Your research has always been spot on.... Thank you.
The product was a miracle. Are you still taking?
I sure hope it comes back somehow soon.
Don't you feel they could have gone after lower fruit than psoriasis and been on the market much sooner? This really surprised me.
So many investors destroyed.... the shorts really knew what they were doing.
Take a look at:
A clear liquid that is classified as a medical device with over 200 applications....CEO is MD, MIT MBA and former Putnam Healthcare fund manager....First human trials sucessful in Europe with Irish government funding 2/3 cost--MIT Tech
Summary: http://www.archtherapeutics.blogspot.com/
Mary I posted on July 14 see http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123954419
I have met Avtar and he lives in California and has been important to Dr. Norchi as a soundboard. He is a Chairman figurehead not involved in day to day.
This is a public company and Avtar and Dr. Norchi own all their original shares. Read my detailed profile of Dr. Norchi.
Norchi has all his eggs in Arch...
Thank you !!!!
AON ALL or NONE
Good question.....no
Karin
Read my bold prior posts.....
Say someone is bidding 80,000 shares at .48 and another at .49 and another at .50 They ignore those bids and fill their own buys other other smaller bids.
Thanks Karin No big blocks over 25,000 shares.
http://www.archtherapeutics.blogspot.com/
I said size meaning over 100,000 share blocks.
ARTH TAPE
I had friends trying to purchase big big quantity under 50 cents---could not get anything !!!!!!!!! What is going on?
Were market markers covering their 1.3 million short?
Anyone have access to trading under $ .50 today?
Very fishy.
Not with Arch
Arch Therapuetics 2015 in Review
22 Press Releases in 2015
27 Press Releases in 2014
Dr. Terrence Norchi did Eight presentations in 2015
Arch CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund.
Old but informative perspective on Norchi—the timing of trials off but at this time it matters little
Ireland's Curam's Press Release
http://www.nuigalway.ie/about-us/news-and-events/news-archive/2016/august2016/curams-first-co-funded-clinical-trial-successfully-completed-with-arch-therapeutics-.html
CÚRAMs First Co-Funded Clinical Trial Successfully Completed with Arch Therapeutics
Wednesday, 24 August 2016
Professor Abhay Pandit, Director of CÚRAM, said: “Clinical trials are an essential component in creating medical devices that realise their full potential and ensuring the safety value of each new development. Without these trials, research cannot be translated into economic, health or societal benefits.
Our collaboration with Arch Therapeutics is very exciting. Leaders within CÚRAM have a successful history working with Arch, and we are delighted to support their drive to commercialization for what should be very important products for the healthcare industry.”
Here is Curam that is FUNDING $2 EUROS to ARCH's $1 EURO for human trials. Curam is backed by Irish government.
http://www.curamdevices.ie/
For me Curam has always been my third party due diligence to validate the Arch technology in addition to the GREAT Dr. KSS. Look at background of people. Plus they have to put their own $$ behind the technology.
Arch AC5 -----A clear liquid that has been classified as a medical device--200+- applications
Summary of Arch: http://www.archtherapeutics.blogspot.com/
Yea the $8 to $12 million additional capital (per SEC filings) required for full human trials in US and Europe of the 200 +- applications for AC5 is a HUGE hurdle. NOT.
Pondering whether AC5 could be used for 3rd and 4th degree burn victims where control of bleeding is critical and difficult?
Arch COMPANY Presentation (page 20 Foot ulcers-Pressure Ulcers, Burns)
http://content.stockpr.com/archtherapeutics/media/a615ba3d0a9c00b0e77d846e84303000.pdf
Totally agree with your statement:
Delivery state of A5C, Dry, wet, liquid etc...a matter of technology development...IMHO once proven it will be stored and delivered in many forms.
Are you going to attend the Rodman Arch presentation? Meet Dr. Norchi?
It does not hurt to have Montel Williams behind your medical device.
How do we get Arch in the limelight?
200+- potential applications for AC5 plus a fleet of new patents and products
Elevator Summary of Arch http://www.archtherapeutics.blogspot.com/
What about gun clubs? People on blood thinners? More????
The market for AC5 is unthinkably large: Every soldier in the world will need a bottle of AC5, every policeman in the world, every ambulance, every gun club, every ER in the world, every first aid kit in every office and manufacturing plant in the world, every person on blood thinners, etc. A billion or more bottles?
Series E Warrant is .438 share and expires 5/26/21. There are no $ .36 warrants. Shares were sold at $.36 5/26/16.
Well the Great Dr. KSS feels that Arch could attain a Billion market cap if it is not gobbled up too early. Well that would be over $6. Means we are 10% there. Nice to dream is guess. The new patents add some firepower. We need institutions.
Dr. Norchi did eight conferences in 2015. IMO he got better at each one. After each of these the stock price went down. To me these are mainly for shareholders to hear some company updates.
You are welcome. Now we have to get the word out. The elevator pitch is suppose to lay out the story. If anyone has any suggestions I am all ears. Thanks
Impossible !!!!!!!!!!!!!!!!!!!!!!!
BTW AC5 is all about Nanotechnology.
"Someone posted that a concern either from the past or in general was about AC5 causing clotting in blood vessels. What, if any research, have you come across?"
Think about it AC5 is a clear liquid that is classified as a medical device. Why? Because it does NOT interact with anything--nothing--zero. It goes on as a barrier that does NOT interact with aanything. Nanotechnology....
So clotting is impossible.
Attributes of AC5
Synthetic peptide
Clear liquid, squirted or sprayed-- Can see and operate through it
Conforms to irregular wound geometry
Physical mechanical barrier (no metabolic activity or chemical activity with the body)
Classified as Medical Device in Europe because of no interaction with the body
No sign of interaction with human cell receptors or cell kinase enzymes
Stops bleeding promptly
Faster time to stop bleeding versus five different popular marketed products
Blood thinner agnostic—only hemostasis product that is.
Efficacy even in presence of “blood thinners”
Bioasborbable
Natural amino acids, non-animal
Enables normal healing
Non-cytotoxic, non-pyrogenic, non-irritant, non-sensitizer
Stores at room temperature
Indefinite shelf life
Simple, effective, versatile, safe universal
Next Generation Medical Technology
There are many other hemostatic agents, but:
* They all rely on using the patient's blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch's AC5 product solves all these problems.
A little ARCH background
So we have a product that is a clear liquid that is classified as a medical device.
The CEO is a Dr., MIT MBA AND former portfolio manager of Putnam's $ 4 BILLION Healthcare Fund.
At Putnam he dealt with numerous institutions. Dr. Norchi understands this market segment.
While at MIT Dr. Norchi sees a Demo by Rutledge Ellis-Behnke PHD of this clear liquid. Even though at this time the product was a Model T Ford compared to today's version of AC5. So in 2006 Dr. Norchi drops ALL opportunities to head up this start-up that becomes knows as Arch.
Here is person who Demo AC5--he mentions how the initial AC5 was not very good compared to current edition
Founder of AC5 Dr. Rutledge Ellis-Behnke PHD 19 minute Presentation Focused on animal Liver
YOU TUBE ViDEO
AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals
The CFO has been at most conferences. He is the person who does sign language of CEO presentation.
Please read. No dilution. Posted before. We just added value of SIX patents for NEW PRODUCTS !!
Future ARCH Financings
I am beginning to doubt whether there will be any future stock financings in light of what I am seeing in recent JV deals.
I see people are attempting to talk the Arch price down talking about stock financings. Look they had $ 5.7 million cash per recent 10-Q. I believe another $ 1.9 series E warrants were exercised recently. They burn $400,000 month.
Study these and note size of numbers and dream about ARTH. Imagine if they did a deal for just 50 of the 200 potential applications.
Remember we only need $ 8 to $ 12 million of additional capital to get all the human trials in Europe AND USA per SEC filings. A JV in Europe could take care of this easily.
Study these recent deals to see how big the numbers have gotten:
Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study (market cap $ 67 million---royalty in high teens)
"This morning, MEI $MEIP is taking the wraps off a development deal with Switzerland’s Helsinn designed to shepherd the HDAC inhibitor pracinostat through a pivotal study. MEI gets $20 million in near-term cash —$15 million up front with a $5 million milestone at the start of the Phase III — along with a $5 million equity investment. And there’s $444 million in milestones on the table for success, along with royalties that can be earned from Helsinn’s marketing efforts"
"Advaxis Inc. ADXS, +5.48% shares spiked 28% in pre-market trade Tuesday after the company announced a $40 million agreement with Amgen Inc. AMGN, -0.15% to develop and commercialize cancer immunotherapy treatment ADXS-NEO. The agreement includes a $40 million upfront payment to Advaxis and a $25 million purchase of the company's common stock by Amgen, along with sales milestone payments of up to $475 million and additional royalty payments based on global sales."
Please do the simple math.
They need $ 8 to $12 million for FULL Europe and US human trials. ALL 200 +- AC5 applications
They burn $ 400,000 a month. Minimum 20 months..... Max 40 months
Watch Dr. Norchi do some of his magic...
Ireland paying 2 Euros for out 1 Euro-----
This last human trial was the equivalent of Phase III for drug company.
So I predict US and Euro trials will be simultaneous in 2017.
What about the SIX new Patents and products??
Which reminds me of a funny Arch story:
So Arch shareholders in say early 2015 felt it only appropriate that Dr. Terrence Norchi CEO MIT MBA and former Putnam Fund manager should show confidence in AC5 by cutting his own throat and applying AC5 on wound and record the entire affair on YouTube so all could watch. They thought this MIGHT help the stock price. Needless to say this never happened.
Of course the favorite of all time:
A Female posted this today about Arch--she works in healthcare for 35 years:
"Being a shareholder in this company, is like watching a cartoon character that begins riding on a go cart and after a minute of animated vehicle morphing he is riding in a Silver Shadow Rolls Royce."